NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Stonegate Capital Partners' Coverage Update on Burcon Nutrascience Corporation (TSX: BU) Q2 FY26
TL;DR
Burcon's commercialization progress and $4M financing provide investors with growth potential as protein demand rises and the company targets $10M+ revenue by 2026.
Burcon achieved first commercial production of Puratein C and FavaPro proteins while scaling Peazazz C, supported by $4M convertible debentures and operational scaling to meet customer demand.
Burcon's plant-based proteins support sustainable food systems by providing nutritious alternatives that can help address global food security and environmental challenges.
Burcon's proteins from canola, fava beans, and peas represent innovative plant-based solutions transforming food manufacturing with diverse applications across nutrition markets.
Found this article helpful?
Share it with your network and spread the knowledge!
The update focuses on Burcon's commercialization progress across multiple plant proteins, including Puratein® C canola protein, FavaPro™ fava protein, and Peazazz® C pea protein, along with recent financing activities and financial performance for Q2 FY26.
Burcon achieved first commercial production and sales of Puratein® C canola protein, first commercial production of FavaPro™ fava protein, and continued scaling of Peazazz® C pea protein at their Galesburg facility.
Burcon generated $0.36M in revenues, representing a 783% increase over the prior year period, with a net loss of $3.59M or $0.28 per share, and ended the quarter with $1.8M in cash and a working capital deficit of $8.2M.
Burcon announced a non-brokered private placement of up to $4.0M in unsecured convertible debentures with 15% annual interest, a $700,000 short-term unsecured loan from a director-related entity at 12% interest, and extended the maturity of its senior secured loan to December 2026.
Using a DCF model with discount rates between 10.50% and 11.00%, Stonegate arrived at a valuation range of $20.29 to $25.66 with a mid-point of $22.61 per share.
Management reaffirmed its CY25 revenue target of $1-3M and its CY26 outlook for $10 million plus revenue with a path to positive cash flow.
Burcon has over 200 active projects progressing through late-stage evaluations across diverse end-market applications in food, beverage, and lifestyle nutrition, with growing demand as customers complete evaluations and move to purchase orders.
The Galesburg facility provides operational flexibility that positions the company to meet evolving customer needs quickly and with consistent quality across multiple protein products.
The 783% revenue growth was driven by initial protein sales and contract manufacturing activities as the company shifts its operational focus toward commercialization.
Curated from Reportable
